Literature DB >> 28567742

Transient ischemic attack and ischemic stroke patients with or without prior stroke.

F Buchwald1, B Norrving1, J Petersson1.   

Abstract

OBJECTIVES: A history of stroke is common in patients with transient ischemic attack (TIA) and ischemic stroke (IS), but there are few reports characterizing this group of patients. We aimed to compare characteristics, risk factors, and secondary preventive treatment in patients with TIA or IS with vs without a history of stroke.
METHODS: Hospital-based data on TIA and IS events, registered from July 2011 to June 2013, were obtained from the Swedish Stroke Register (Riksstroke). Previous stroke was not specified as hemorrhagic or ischemic.
RESULTS: A history of stroke was present in 19.3% (2892/15012) of TIA and 24.6% (10853/44169) of IS patients. Patients with prior stroke were older, more often male, and more likely to have atrial fibrillation (AF) (TIA: 27.4% vs 16.4%; IS: 36.1% vs 28.0%), hypertension (TIA: 77.5% vs 56.4%; IS: 74.2% vs 59.0%), and diabetes mellitus (TIA: 22.2% vs 14.2%; IS: 26.3% vs 19.5%) compared with those without (all differences P<.0001). At discharge, patients with prior stroke were more often treated with antihypertensive drugs than those without, whereas proportions treated with statins were similar in both groups. Patients with AF and prior stroke were less often treated with oral anticoagulant (OAC) medication than those without prior stroke.
CONCLUSIONS: Both in TIA and IS, vascular risk factors were more common in patients with a history of stroke compared with those without. In contrast to other secondary preventive medications, OAC treatment in the presence of AF was underutilized in patients with a history of stroke.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  atrial fibrillation; cerebrovascular diseases; history of stroke; ischemic stroke; secondary prevention; transient ischemic attack

Mesh:

Year:  2017        PMID: 28567742     DOI: 10.1111/ane.12782

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  1 in total

1.  Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms.

Authors:  Valerio De Stefano; Alessandra Carobbio; Vincenzo Di Lazzaro; Paola Guglielmelli; Alessandra Iurlo; Maria Chiara Finazzi; Elisa Rumi; Francisco Cervantes; Elena Maria Elli; Maria Luigia Randi; Martin Griesshammer; Francesca Palandri; Massimiliano Bonifacio; Juan-Carlos Hernandez-Boluda; Rossella Cacciola; Palova Miroslava; Giuseppe Carli; Eloise Beggiato; Martin H Ellis; Caterina Musolino; Gianluca Gaidano; Davide Rapezzi; Alessia Tieghi; Francesca Lunghi; Giuseppe Gaetano Loscocco; Daniele Cattaneo; Agostino Cortelezzi; Silvia Betti; Elena Rossi; Guido Finazzi; Bruno Censori; Mario Cazzola; Marta Bellini; Eduardo Arellano-Rodrigo; Irene Bertozzi; Parvis Sadjadian; Nicola Vianelli; Luigi Scaffidi; Montse Gomez; Emma Cacciola; Alessandro M Vannucchi; Tiziano Barbui
Journal:  Blood Cancer J       Date:  2018-02-28       Impact factor: 11.037

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.